Compare Invesco DB Oil Fund (DBO) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Illumina, Inc. — how do they compare? Invesco DB Oil Fund trades at $21.06, while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| DBO | ILMN | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $23.80 | $205.10 |
52-Week Low | $11.98 | $91.00 |
Market Cap | — | $29.12B |
Enterprise Value | — | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $19.59, down 0.41% on the day, with a bearish technical signal from moving averages and oscillators showing neutrality. The stock faces resistance at $20 and support at $19. Recent news highlights oil price volatility due to Middle East tensions, particularly the Strait of Hormuz deadlock, which may impact energy sector stocks like DBO.
The outlook for DBO is cautious amid geopolitical risks and technical bearishness. Investment opportunities hinge on resolution of oil supply constraints, while risks include prolonged Middle East instability and potential earnings pressure from fluctuating crude prices. Wall Street sentiment appears mixed, with no clear consensus on near-term direction.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
